Physician profile
Brian J Macfalda
NPI 1013130053
$1,235.08
in general payments reported to CMS, 2019-2025
11 companies · $79.54 in 2025
The $79.54 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $377 · 2020: $551 · 2022: $89.15 · 2023: $24.97 · 2024: $113 · 2025: $79.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $217.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $495.00 | 2020 | |
| Emd Serono, INC. | $141.35 | 2019-2020 | |
| Lundbeck LLC | $80.01 | 2024 | Vyepti |
| Neurelis, INC. | $79.54 | 2025 | Valtoco |
| Lilly USA, LLC | $76.09 | 2019 | |
| Abbvie INC. | $74.70 | 2022-2023 | |
| Genentech USA, INC. | $69.40 | 2019-2020 | |
| Ucb, INC. | $69.29 | 2019 | |
| Janssen Pharmaceuticals, INC | $64.43 | 2019 | |
| Novartis Pharmaceuticals Corporation | $45.85 | 2019-2024 | |
| Teva Pharmaceuticals USA, INC. | $39.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Macfalda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.